ARTICLE | Clinical News

Torisel temsirolimus: Phase III data

June 9, 2008 7:00 AM UTC

In an open-label, international Phase III trial in 162 evaluable patients, the higher of two Torisel doses (175 mg IV followed by 75 mg IV) met the primary endpoint of a significant increase in PFS vs...